MedPath

Effect of Inhalational Anesthesia Versus Total Intravenous Anesthesia on Blood Glucose in Type 2 Diabetes Patients

Not Applicable
Completed
Conditions
Type 2 Diabetes Mellitus (T2DM)
Thoracic Surgery
Interventions
Drug: Inhalational anesthesia
Registration Number
NCT06613893
Lead Sponsor
Ain Shams University
Brief Summary

The aim of this study is to compare the effect of total intravenous anesthesia (TIVA) and inhalational anesthesia (IHA) as maintenance anesthesia on blood glucose level and complications in type 2 diabetic patients undergoing thoracic surgery . All participants had to understand and give written informed consent , and ethical committee approval (of Faculty of Medicine, Ain Shams University) will be obtained before participants allocation.

Detailed Description

* Type of Study: prospective , randomized .

* Study Settings: Ain Shams University hospitals, Cairo, Egypt.

* Study period: 12 months starting from janurary 2024 .

* Study Population: All adult type 2 diabetic patients (30-70 year old) with class II,III based on the American Society of Anesthesiologists (ASA) physical status undergoing elective thoracic surgeries will be randomly assigned into one of the following groups using computer generated codes and opaque sealed envelopes:

1. Group A will receive total inravenous anesthesia (TIVA).

2. Group B will receive inhalational anesthesia (IHA)

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
42
Inclusion Criteria

Age 30 - 70 years Sex: Both sexes Pateints with type 2 diabetes mellitus controlled with oral hypoglycemics Patients with ASA classificaion II,III Duration of surgery (≥2 h)

Exclusion Criteria

Declining to give written informed consent ASA classification Ⅳ to V Severe systemic diseases Metabolic disorders, diabetic ketoacidosis or hyperglycemia (fasting blood glucose more than 140 mg/dl) Hepatic and/or renal dysfunction Neuromuscular disease Pancreatic cancer History of malignant hyperthermia Emergency surgery Ischemic heart disease and valvular heart disease Body mass index more than 40 Diabetic patients on insulin therapy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group B will receive inhalational anesthesia (IHA)Inhalational anesthesiapatients in this group will receive inhalational anesthesia using isoflurane, tested variables will be measured according to the protocol
Primary Outcome Measures
NameTimeMethod
Blood glucose levels in milligrams per decilitre (mg/dl) at different time pointsImmediate preoperative till 48 hours after recovery from anesthesia

Blood glucose levels in milligrams per deciliter at different time points: preoperative (T0), post-intubation (T1), 1st , 2nd and 3rd hour after the start of the operation (T3, T4 and T5, respectively), 1st hour after the operation (T6) , 2nd hour after the operation (T7), 1st and 2nd day after the operation (T8, T9)

Secondary Outcome Measures
NameTimeMethod
The incidence of postoperative complicationsThe complications will be assessed on the first, third and seveth post-operative day

The complications that will be tested Acute coronary syndrome. Stroke. acute kidney injury. stress gastric ulcer. surgical site infection. Hypoglycaemia (blood glucose level below 70 mg/dL). Hyperglycemia (fasting blood glucose level greater than 125mg/dL while 2 hours postprandial greater than 200 mg/dL).

Postoperative nausea and vomiting . postoperative pulmonary complications including atelectasis, pneumonia and respiratory failure

Serum insulin level in picomoles per litre (pmol/l)30 min before induction of anesthesia and 30 min after surgery and recovery from anesthesia

serum insulin level (pmol/l) 30 min before and 30 min after surgery

Serum cortisol level in micrograms per decilitre (mcg/dl)30 min before induction of anesthesia and 30 min after surgery and recovery from anesthesia

serum cortisol level (mcg/dl) 30 min before and 30 min after surgery

Trial Locations

Locations (1)

Ain Shams University

🇪🇬

Cairo, Egypt

© Copyright 2025. All Rights Reserved by MedPath